Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2095215 Target Snapshot

Ribonucleoside-diphosphate reductase RR1 · PROTEIN COMPLEX GROUP · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
205Compounds
34Assays
0Approved Drugs
121.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Ribonucleoside-diphosphate reductase RR1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P23921. Start with cancer, then reuse UniProt P23921 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt P23921 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 4 linked drugs
Open source guide
Disease program
cancer

Ribonucleoside-diphosphate reductase RR1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include CLOFARABINE, FLUDARABINE PHOSPHATE, GEMCITABINE HYDROCHLORIDE, TEZACITABINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Protein anchor
Ribonucleoside-diphosphate reductase large subunit

Ribonucleoside-diphosphate reductase large subunit

Review this target as Ribonucleoside-diphosphate reductase RR1, mapped to UniProt P23921. ChEMBL maps the protein component as Ribonucleoside-diphosphate reductase large subunit. Sequence length is 792 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P23921 Protein 792 aa
Open protein block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Ribonucleoside-diphosphate reductase RR1 as ChEMBL target CHEMBL2095215, mapped to UniProt P23921. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Ribonucleoside-diphosphate reductase RR1
PROTEIN COMPLEX GROUP · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2095215
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P23921
Ribonucleoside-diphosphate reductase large subunit
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Ribonucleoside-diphosphate reductase RR1 is the right protein anchor across sources, using UniProt P23921 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRibonucleoside-diphosphate reductase RR1
Target TypePROTEIN COMPLEX GROUP
OrganismHomo sapiens
UniProtP23921
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRibonucleoside-diphosphate reductase large subunit
UniProt AccessionP23921
Component TypeProtein
Sequence Length792 aa

Ribonucleoside-diphosphate reductase large subunit

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Ribonucleoside-diphosphate reductase RR1, mapped to UniProt P23921. ChEMBL maps the protein component as Ribonucleoside-diphosphate reductase large subunit. Sequence length is 792 aa.

Mapped IDP23921
Review nameRibonucleoside-diphosphate reductase RR1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Ribonucleoside-diphosphate reductase RR1 shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
4 linked drugs · 4 direct · 4 efficacy
Linked drugCLOFARABINE
Linked drugFLUDARABINE PHOSPHATE
Linked drugGEMCITABINE HYDROCHLORIDE
Linked drugTEZACITABINE
Approved-linked Approved
neoplasm
4 linked drugs · 4 direct · 4 efficacy
Linked drugCLOFARABINE
Linked drugFLUDARABINE PHOSPHATE
Linked drugGEMCITABINE HYDROCHLORIDE
Linked drugHYDROXYUREA
Approved-linked Approved
acute lymphoblastic leukemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugCLOFARABINE
Linked drugFLUDARABINE PHOSPHATE
Linked drugHYDROXYUREA
Approved-linked Approved
chronic lymphocytic leukemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugCLOFARABINE
Linked drugFLUDARABINE PHOSPHATE
Linked drugMOTEXAFIN GADOLINIUM
Approved-linked Approved
chronic myelogenous leukemia
3 linked drugs · 3 direct · 3 efficacy
Linked drugCLOFARABINE
Linked drugFLUDARABINE PHOSPHATE
Linked drugHYDROXYUREA
Approved-linked Approved
breast cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugFLUDARABINE PHOSPHATE
Linked drugGEMCITABINE HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include CLOFARABINE, FLUDARABINE PHOSPHATE, GEMCITABINE HYDROCHLORIDE, TEZACITABINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC50104.0
KI1.0
EC5016.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL336289 9.22 IC50 0.6 Preclinical
CHEMBL96993 9.15 IC50 0.7 Preclinical
CHEMBL98729 9.0 IC50 1.0 Preclinical
CHEMBL1169533 8.7 IC50 2.0 Preclinical
CHEMBL133754 8.52 IC50 3.0 Preclinical
CHEMBL305199 8.52 IC50 3.0 Preclinical
CHEMBL95998 8.4 IC50 4.0 Preclinical
CHEMBL335164 8.3 IC50 5.0 Preclinical
CHEMBL95766 8.3 IC50 5.0 Preclinical
CHEMBL134961 8.22 IC50 6.0 Preclinical
Distribution

pChEMBL Value Distribution

12
5.0
8
5.5
11
6.0
3
6.5
8
7.0
9
7.5
8
8.0
3
8.5
3
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

34
Total Assays
85
Tested Compounds
2
Assay Types
Binding — 31 assays, 85 compounds
BAO Format Assays Compounds Avg pChEMBL
protein complex format 28 71 6.4
assay format 3 14 4.5
Functional — 3 assays, 8 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 8 4.8
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine